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Objective: Knee osteoarthritis is a major cause of disability and pain. This phase III, double-blind (patient
and observer blinded,) multicenter, randomized, non-inferiority study was conducted to demonstrate the
non-inferiority of the highly puriﬁed intra-articular injection of hyaluronic acid (Sinovial) in compar-
ison to Hylan G-F20 (Synvisc) in the treatment of knee osteoarthritis.
Methods: A total of 381 patients were randomly assigned to receive either the test drug, 16 mg/2 ml
(0.8%) highly puriﬁed ia hyaluronic acid of biofermentative origin (Sinovial), or the comparative drug,
16 mg/2 ml of 0.8% hylan G-F20 (Synvisc). The duration of the treatment was 2 weeks (three injections
at 1-week interval), followed by an observation period of 6 months.
The primary efﬁcacy variable was the improvement in mean Western Ontario and McMaster Universities
(WOMAC) pain subscore from baseline to the ﬁnal visit (week 26), compared between the two treatment
groups. The acceptable margin for non-inferiority was chosen to be 8 mm.
Results: At week 26, WOMAC pain subscores decreased by a mean of 32.5 for both Sinovial and Synvisc.
These results met prespeciﬁed criteria for non-inferiority for both the Intent-to-Treat and Per-Protocol
populations. There were no statistically signiﬁcant differences between groups at 26 weeks, although
Sinovial-treated patients tended to have a slightly better outcome for select variables, as they did at
earlier time-points, some of which reached statistical signiﬁcance. Both hyaluronic acid preparations
were well-tolerated, with no statistically signiﬁcant differences in tolerability proﬁle between groups.
Conclusion: Sinovial and Synvisc treatments were found to be equivalent, both in terms of efﬁcacy and
safety.
Clinical Trial Number: NCT00556608 (ClinicalTrials.gov Identiﬁer).
 2011 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Current treatments for knee osteoarthritis include analgesics,
non-steroidal anti-inﬂammatories, exercise, physiotherapy,
weight-relieving braces and total knee arthroplasty1,2. However,
most currently used treatments have limited tolerability3 and their
efﬁcacy is limited to relieving pain. Recently, attention has turned
to treatments with the potential to offer disease-modifying activity,
such as viscosupplementation, a therapeutic modality ﬁrst devel-
oped in the 1960s4.to: K. Pavelka, Institute of
public. Tel: 420-234075244;
Elsevier Ltd on behalf of OsteoartViscosupplementation is based on restoration of the synovial ﬂuid
environment, allowing restoration of normal joint structure and
function5. Hyaluronic acid is a large glycosaminoglycan that naturally
occurs in the synovial ﬂuid6 and plays an important physiological role
in synovial joints7,8. In patients with knee osteoarthritis, the average
molecular weight and concentration of hyaluronic acid is reduced4,9.
Viscosupplementation with hyaluronic acid is a well-established2,5,9
and widely used therapy for osteoarthritis, and is recommended by
both the American College of Rheumatology and the European League
Against Rheumatism for this indication10,11. Intra-articular hyalur-
onans have been approved by the US Food and Drug Administration
(FDA) since 1997 for relief of osteoarthritis knee pain1, and there are
a numberof different hyaluronic acid preparations for the treatment of
knee osteoarthritis. These include Hylan G-F20 (Synvisc), a G-F20
preparation that comprises two cross-linkedderivatives of hyaluronanhritis Research Society International.
K. Pavelka, D. Uebelhart / Osteoarthritis and Cartilage 19 (2011) 1294e1300 1295with a molecular weight of 6,000 kDa12, and Sinovial, a chemically
non-modiﬁed sodium hyaluronate, with a molecular weight of
800e1,200 kDa.
The purpose of this non-inferiority study was to evaluate the
clinical efﬁcacy and general tolerability of Sinovial relative to an
already marketed producted, Synvisc, when administered to
patients with symptomatic knee osteoarthritis. Synvisc was
chosen as the comparator because it is widely used in several
European countries for knee osteoarthritis13. The non-inferiority
trial design was adopted because of ethical and methodological
reasons detailed in the discussion section.
Method
Study design and patients
This was a multicenter, phase III, double-blind, controlled,
randomized, parallel-group, non-inferiority study in patients with
knee osteoarthritis. The study comprised patients from the Czech
Republic, France, Italy, Switzerland, the SlovakRepublic andGermany
(see the acknowledgments for a list of participating physicians and
study centers). After obtaining written informed consent, patients
underwent a physical and knee examination and a thoroughmedical
history was obtained. Five to 10 days after screening, patients who
required medication washout or X-rays were subjected to baseline
evaluation.
Included patients were outpatients aged between 40 and
81 years’ with symptomatic primary knee osteoarthritis, with
symptoms present in the target knee for at least 3 months. All
patients were required to have an American Colleague of Rheuma-
tology (ACR) clinical and radiological-based diagnosis of target-knee
osteoarthritis, and Kellgren & Lawrence grade 2e3 osteophytes
within 6 months of screening. Included patients were thosewho had
failed to respond sufﬁciently to analgesics and/or Non-steroidal
Antirheumatic Drugs (NSAIDs) taken regularly, or those who
responded but who were unable to tolerate such treatment. Mean
WOMAC pain subscore at the target knee was required to be
40mm and <80mm on a 100 mm visual analog scale (VAS)
following NSAIDs/analgesic washout, with mean WOMAC pain
subscore <30mm on a 100 mm VAS in the contralateral knee
(i.e., non-target knee).
Patientswere excluded due to: BodyMass Index (BMI) 32 kg/m2,
secondary target knee osteoarthritis, predominantly femoral-patella
knee pain mainly related to femoral patellar syndrome at the target
knee, no remaining joint spacewidth at the target knee, symptomatic
hip osteoarthritis or other condition that would interfere with study
assessments, severe varus/valgus deformity in the target knee, history
or current evidence of other joint diseases, such as inﬂammatory,
infective or metabolic joint disease, concomitant rheumatic disease,
signiﬁcant injury to the target knee in the past 6 months, previous
joint replacement or arthroplasty on the target knee, arthroscopy,
osteotomy or surgery on the target knee in the past year, any surgical
procedure scheduled in the next 6 months, venous or lymphatic stasis
in the relevant limb, skin infection, disease or trauma at the injection
site, systemic or intra-articular (target knee) corticosteroids in the past
3 months, intra-articular corticosteroids (contralateral knee) in the
past 4 weeks, viscosupplementation to the target knee in thepastyear,
initiation of target knee physical therapy in the past 3 months, initi-
ation/change in dose of symptomatic slow-acting drugs for osteoar-
thritis therapy, ongoing anticoagulant therapy, chronic/recurrent use
of NSAIDs, analgesics or narcotics other than for osteoarthritis of the
target knee, history of allergy or hypersensitivity to hyaluronic acid,
paracetamol or avian proteins, participation in a clinical study within
the past 3 months, pregnant or lactating women, and women of
childbearing potential not willing to use adequate contraception.The study was approved by the ethics committee of all partici-
pating study centers. All patients gave theirwritten informedconsent
to participate in accordance with the Declaration of Helsinki.
Intervention
Eligible patients were assigned a three-digit randomization
number for identiﬁcation purposes. Patients were given a 1-month
supply of rescue medication and instructed not to consume this
within the 24 h prior to study visits. Rescue medication use was to
be recorded in a patient diary, along with concomitant medication
usage, adverse events, lifestyle changes and the weekly global pain
assessment. Patients were randomized to receive once weekly for
3 weeks either 16 mg/2 ml (0.8%) of highly puriﬁed intra-articular
hyaluronic acid of biofermentative origin, a linear unbranched
polysaccharide chain with a mean Molecular Weight (MW) of
800e1,200 kDa, Sinovial (IBSA, Switzerland and Laboratories Gen-
évrier, France) or 16 mg/2 ml (0.8%) of intra-articular hylan G-F20,
a cross-linked polysaccharide chain containing hylan A with a mean
MW of 6,000 kDa and hylan B a hydrated gel, Synvisc (Genzyme
Biosurgery, Ridgeﬁeld, NJ, USA). Control visits were carried out at 4,
12 and 26 weeks.
Prior and concomitant therapy
Ongoing and/or initiation of new concomitant treatment was
permitted if essential for patient health, and not speciﬁed in the
exclusion criteria. Prohibitedmedications included anti-coagulants,
systemic NSAIDs, analgesics other than paracetamol, narcotics,
systemic and intra-articular corticosteroids, intra-articular injec-
tion of the target knee, topical anti-inﬂammatories and analgesics
at the target knee, articular lavage of the target knee, newly initi-
ated symptomatic slow-acting drugs for osteoarthritis or alteration
in dosage (long-term therapy at stable dosage acceptable), newly
initiated physical therapy and alternative medicines.
Efﬁcacy outcomes
Theprimaryefﬁcacyvariablewaschange frombaseline inWestern
Ontario andMcMaster Universities (WOMAC) Index pain subscore at
26 weeks. The WOMAC Index is a standardized and validated meth-
odology for assessing pain associated with osteoarthritis, and is
routinely used as a primary end-point in clinical trials studying the
effect of drugs and devices for this particular indication14.
Change from baseline in theWOMAC total score, and in the pain,
stiffness and function subscores were assessed as secondary efﬁ-
cacy variables. Changes from baseline were also assessed for the
Lequesne Algofunctional Index15, patient assessment of global pain
(deﬁned as the amount of pain during the previous 24 h, scored on
a 0e100 mm VAS, with 0 representing no pain and 100 unbearable
pain)16 and for patient assessment of global status scored on
a 0e100 mm VAS, with 0 representing very poor global status and
100 very good global status16. Global status was also assessed by
the investigator and scored on a 5-point scale, with 0 being very
poor and 4 being very good. Additional efﬁcacy variables were
Percentage Sum of the Pain Intensity Differences (SPID%) calculated
on the basis of weekly assessment of global pain over the 6-month
study period, according to the following formula:
SPID% ¼ Sum of Pain Intensity Differences
Maximum Scale of Pain Intensity Trial Duration
 100
and paracetamol consumption for target knee osteoarthritis.
Patient assessment of treatment satisfaction was also evaluated,
Trial profile 
381 randomised 
192 Sinovial
®
189 Synvisc
®
6 major protocol 
deviations 
1 adverse event 
2 patient’s desire 
(4 lack of efficacy) 
(4 worsening) 
183 Sinovial
®
(PP including 8 patients drop-
out for lack of efficacy / 
worsening) 
171 Synvisc
®
(PP including 5 patients drop-
out for lack of efficacy / 
worsening)
11 major protocol  
deviations
1 adverse events 
3 patient’s desire 
1 other reasons 
2 lost of view 
(3 lack of efficacy) 
(2 worsening) 
406 patients screened 
Fig. 1. Flow chart of patient disposition.
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satisﬁed. Overall response rate was assessed at 12 and 26 weeks
based on the OMERACT-OARSI response criteria17. There were no
changes to the outcome measurements after the trial commenced.
Safety
Patients were asked at each visit if they had experienced any
Adverse Events (AEs) since the last visit and were asked about pain at
injection site immediately after the injection, and to rate their
perceivedpainonascaleof0 (nopain) to10(worstpossiblepain). Local
tolerabilitywasalsoassessed,bythepatientandthe investigator,based
on a 5-point scale, with 0 being very poor and 4 being very good.
Sample size
For improvement in mean WOMAC Index pain subscore from
baseline, the protocol-deﬁned non-inferiority margin for the differ-
ence between Sinovial and Synvisc was 8 mm on a VAS ranging
from 0 to 100 mm. This non-inferiority margin is less than the
minimum clinically perceptible difference, usually considered to be
10 mm for the WOMAC pain subscore18, and lower than the
minimum clinically important improvement of 10e20 mm19e21.
Assuming a standard deviation of 21 mm for both groups22, with
two-sided a¼ 0.05 and b¼ 0.10 (90% power), the required sample
size was estimated to be 145 patients per group. The protocol
proposed a total of 200 patients per group to allow for a protocol
violation rate of up to 25%.
The Intent-to-Treat (ITT) population comprised all patients who
received at least one dose of Sinovial or Synvisc. The Per-Protocol
(PP) populationwas a subgroup of patients with no serious protocol
violations selected from the ITT group in a blinded fashion prior to
breaking the randomization code. Patients failing to return for the
week 26 visit were excluded from the PP population only if their
absence could not be attributed to treatment failure.
Randomization and blinding
Patients were randomized according to a Statistical Analysis
System (SAS) generated randomization list prepared by IBSA inwhich
patients were assigned to treatment, at a 1:1 allocation ratio, at each
site in blocks of four. Randomization numbers were assigned chro-
nologically based upon order of study enrollment. An investigator
who was blind to treatment allocation enrolled the study partici-
pants, and an unblinded investigator performed the injections.
Because of the evident differences in the marketed packaging
between Sinovial and Synvisc, it was not possible to use a full
double-blind design. However, the study is considered to be
a double-blind study in that both the patient and the observer were
blinded. More speciﬁcally, neither the investigators nor the patients
had contact with the study products, which were delivered to the
study centers in identical, sealed, unmarked boxes containing three
blister-packaged syringes. Separate individuals performed the
injection and assessments, and the patient was either blind folded
or separated from the physician by an obstructive operative ﬁeld
during the injection process.
Statistical methods
To determine the appropriate statistical test for non-inferiority,
the change from baseline improvement in the WOMAC pain score
was tested for normality using the ShapiroeWilk test on the entire
patient population. If the distributionwas not signiﬁcantly different
(P< 0.05) fromnormality, itwas considered appropriate to calculate
the 95% conﬁdence interval (CI) using Analysis of Variance (ANOVA)with Least-Squares means (equivalent to Student’s t test). If the
distribution departed signiﬁcantly from normality, the nonpara-
metric HodgeseLehmann method was used. Other continuous
variables were analyzed using ordinary hypothesis-testing statis-
tical methods. All variables were analyzed using ANOVA and the
nonparametric Wilcoxon rank-sum test. Binary variables were
analyzed using the Fisher exact test.
Results
Patients were recruited from November 2007 to January 2009,
with the last patient completing the study in July 2009. A total of
381 patients were randomized at the 23 sites, all but one of whom
received at least one intra-articular injection of the assigned hya-
luronic acid preparation (Fig. 1).
Two populations were analyzed; the ITT population comprising
all 380 patients who received at least one injection of Sinovial or
Synvisc, and the PP population, which excluded 27 patients with
serious protocol violations, as follows: a WOMAC score >30 in the
contralateral knee at screening/baseline (n¼ 9), a WOMAC score
<40 in the target knee at screening/baseline (n¼ 6), patient
voluntary study withdrawal (n¼ 5), an adverse event, effusion
>15 ml in the target knee, lost to follow-up (two each) and an
inclusion error (n¼ 1). All ITT patients received at least one
intra-articular injection of either Sinovial or Synvisc, with two
patients in the Sinovial group not receiving a second and third
injection, compared with three and ﬁve Synvisc patients,
respectively. Overall, 99.0% of the Sinovial group and 97.3% of
those assigned to Synvisc were given all three injections.
Baseline data
The average age of the 380 ITT patients was 65 years (range
41.8e80.9), the majority were female (72.9%) and the predominant
prior/ongoing medical condition was hypertension (Table I).
Patient-assessed global pain scores at screening and baseline aver-
aged 65.3 and 65.6, respectively, on a 100-point scale, while other
indices of disease severity were also suggestive of mild to moderate
target knee osteoarthritis. The baseline characteristics of the PP
populationwere virtually identical to their ITT counterparts (Table I).
Concomitant medications
Prior to study enrollment and continuing after intra-articular
administration of the assigned study medication, 242 (63.7%) of the
Table I
Demographic and baseline clinical characteristics of all patients*
Characteristics Treatment group
Sinovial
(n¼ 192)
Synvisc
(n¼ 188)
Age (years) 65.1 9.1 64.9 8.7
BMI (kg/m2) 27.1 3.1 27.0 3.1
Women, no. (%) 139 (72.4) 138 (73.4)
Post-menopausal 134/139 134/138
Duration from diagnosis (years) 6.3 5.8 5.6 5.6
Involvement of contralateral knee (%) 66.1 66.0
Location target knee, no. (%)
Right 102 (53.1) 98 (52.1)
Left 90 (46.9) 90 (47.9)
K/L grade, no. (%)
2: minimal 85 (44.3) 85 (45.2)
3: moderate 107 (55.7) 103 (54.8)
Medication usage in prior 3 months (%) 63.5 59.6
Prior target knee treatments (%)
Ambulatory aid 2.10 5.9
Knee surgery 12.5 13.3
Prior medical procedures 24.0 20.7
Therapeutic drug use 90.1 92.0
Non-drug therapy 9.4 8.5
WOMAC score, mm
Pain 55.2 10.8 55.5 10.9
Stiffness 50.1 19.1 50.1 19.4
Function 53.1 14.6 53.6 13.9
Total 53.3 12.9 53.7 12.5
Lequesne algofunctional index 11.5 3.0 11.6 3.2
Patient global pain, 100-mm (VAS) 64.5 14.2 66.7 14.0
There were no statistically signiﬁcant differences between groups.
* Except where indicated otherwise, values are the mean SD.
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Fig. 2. Change from baseline in WOMAC scores e (a) ITT and (b) PP populations.
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Concomitantmedications discontinuedbefore theﬁrst intra-articular
treatment or begun sometime thereafter were generally pain
remitting innature. Signiﬁcant intergroupdifferences in concomitant
medications consumption were limited to the proportion of patients
on a cardiovascular medication, with more Sinovial patients being
treated with a calcium channel blocker over the course of the study,
while the converse occurred for angiotensin-converting enzyme
inhibitors.
Primary efﬁcacy outcome
At week 26, WOMAC Index pain subscores decreased from
a mean of 55.5 in the Synvisc group to 23.1, a mean difference of
32.5, with corresponding values of 55.2 and 22.7 at baseline and
week 26, respectively, for Sinovial, a mean difference of 32.5
(Fig. 2). These results corresponded to a between-group mean
difference in change frombaseline at 26 weeks of 0.0 (95% CI4.7 to
4.8). The WOMAC Index pain subscore results met the prespeciﬁed
criteria for non-inferiority, irrespective of the patient population
analyzed. If actual scores were considered, rather than the change
from baseline, results again demonstrated non-inferiority. Taking
the WOMAC scores at 4 weeks and at 12 weeks, there were no
differences demonstrated between the two treatment groups, with
values of 25.4 and 22.7, respectively, for Sinovial, compared with
27.1 and 24.6, respectively, for Synvisc, corresponding to
between-group mean differences of 1.3 (95%CI 2.6 to 5.3) and 1.6
(2.8 to 6.0), at 4 and 12 weeks, respectively. The statistical meth-
odology employed (parametric vs nonparametric) again made no
impact on the demonstration of non-inferiority of these two hya-
luronic acid preparations. Theworst-case lower bound CI for the ITT
comparisons was 6.2 (ANOVA derived, actual scores at 12 weeks),
while aworst-case value of5.8was obtained for the PP population
(ANOVA derived, change from baseline scores at 26 week).Secondary efﬁcacy outcomes
Patient scores for the WOMAC Questionnaire Function and
Stiffness components, as well as total score did not differ signiﬁ-
cantly between treatment groups at any time point, with changes
from baseline at 26 weeks for function, stiffness and total score of
28.0, 25.8 and 28.8, respectively, for Sinovial, and 28.2, 25.7 and
28.8 for Synvisc in the ITT population. For the PP population,
changes from baseline at 26 weeks for function, stiffness and total
score were 29.0, 26.6 and 29.7, respectively, for Sinovial, with
corresponding values of 29.7, 26.7 and 30.5 for Synvisc. Lequesne
Questionnaire total score did not differ signiﬁcantly between
treatments at 26 weeks, with a change from baseline of 3.9 for
Sinovial and 3.6 for Synvisc for the ITT population, and corre-
sponding values of 4.0 and 3.7, respectively, for the PP population.
At 12 weeks, the change from baseline in Lequesne total score was
signiﬁcantly higher for Sinovial than for Synvisc, at 3.9 vs 3.4
(P¼ 0.049; Fig. 3), although no signiﬁcant between-group differ-
ences were apparent at the 4-week time point: these signiﬁcant
differences were not seen in the PP population.
Decreases in patient-assessed global pain did not differ between
groups at any time point, with decreases in the ITT population from
64.5 to 26.9 in the Sinovial group and 66.7 to 30.5 in the Synvisc
group. Similar results were obtained for the PP population. For
patient-assessed global status, measured using a 100-point VAS,
with 0 being very poor status and 100 very good status, there were
improvements from baseline of a similar magnitude for both
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Table II
Rescue medication usage
Sinovial
(% of patients)
Synvisc
(% of patients)
ITT PP ITT PP
Rescue medication/Target knee
Screen e baseline 50.6 50.6 48.8 48.7
Baseline e 4 weeks 51.9 52 58.8 58
4e12 weeks 44 44 46.6 46.4
12e26 weeks 41.9 42.2 49.1 48.8
Baseline e 26 weeks 64.2 64.8 69.9 69.4
Total rescue medication usage
Screen e baseline 34.4 34.4 35.6 33.9
Baseline e 4 weeks 57.4 57.7 64.1 62.9
4e12 weeks 51.1 51.4 57.5 56.8
12e26 weeks 49.7 49.7 55.7 54.8
Baseline e 26 weeks 67.9 68.7 76.6 75.3
There were no statistically signiﬁcant difference between groups.
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Sinovial and from 45.0 to 69.4 for Synvisc in the ITT population,
with similar results for the PP population.
Investigator assessment of global status was the same for both
treatment groups at baseline, 4 weeks and 26 weeks, but at
12 weeks, Sinovial-treated patients were judged to have had
a signiﬁcantly better overall response, primarily due to a higher
percentage being characterized as having a very good outcome, at
37% and 27.2% for Sinovial, compared with 25% and 26.4% for
Synvisc, for the ITT and PP populations, respectively, (P-values
0.014 and 0.044, respectively). Overall, 79.7% and 79.8% of the ITT
and PP patients given Sinovial were judged by the investigator at
26 weeks to have had a good or very good response, comparedwith
70.7% and 72.0% for Synvisc.
There were no statistically signiﬁcant differences between
groups for rescue medication usage, overall or speciﬁcally for target
knee pain (Table II), although total rescue medication usage was
higher for Synvisc than Sinovial for the period from baseline to
26 weeks, with 76.6% compared with 67.9% (P¼ 0.065) of patients
using such medication, respectively, for the ITT population and
68.7% compared with 75.3% (P¼ 0.192) for the PP population. In
terms of paracetamol use, both the percentage of patients requiring
such treatment for target knee pain and the number of tablets
consumedwere somewhat reduced for Sinovial following the ﬁrst
intra-articular injection (tablets for target knee pain Y w30% and
37%, respectively, at 4 and 12 weeks, for both ITT and PP subsets),
but these differences were not accompanied by an overall reduction
in total consumption of medications.At 4 and at 12 weeks the proportion of patients very satisﬁed
with Sinovial treatment was w39% and 47%, respectively, while
that for Synvisc wasw30% and 35%. The OMERACT-OARSI overall
success rate was the same for both Sinovial and Synvisc (ITT,
85.9% vs 82.4%; PP, 87.4% vs 86.0%, respectively).
Subgroups
The relationship between change from baseline inWOMAC pain
subscore and select patient baseline variables was explored in
individual and multiple regression models. Of the 36 variables
evaluated, only six were found in simple regression to be signiﬁ-
cantly (all positively) correlated with the primary outcome
measure, the strongest predictor being the patient’s WOMAC pain
subscore at baseline, followed by days off-work due to pain in the
previous year, the presence of sclerosis, varus knee, ﬂexion, and
pain duration. In the ﬁnal backward regression model (r2¼ 0.124),
four of the 36 variables provided signiﬁcant explanatory power for
patient response to therapy, but the overall effect on comparisons
in outcome for Sinovial and Synvisc-treated patients was unaf-
fected by mean adjustments due to the presence of the retained
covariates in the model (non-parametric¼ 37.8 vs 37.2, respec-
tively, in absolute change from baseline, CI¼3.1 to þ4.9; para-
metric¼ 32.3 vs 32.6, respectively, CI¼4.8 to þ4.2).
Additional analyses revealed that patients tended to have
a better response to either preparation of intra-articular hyaluro-
nate if they were lighter in weight, visited their doctors more often
or took more time-off from work, had more severe disease as
indicated by the presence of sclerosis or an excessive number of
osteophytes, were bow-legged, or had greater WOMAC pain at
baseline, in the absence of signiﬁcant treatment by subgroup
interaction effects for any of these independent variables. Consis-
tent with the results of the intergroup comparison of the primary
efﬁcacy variable, the lower bound of the 95% CI for any of the
adjusted, treatment group mean comparisons was always greater
than the 8 mm delta proposed for this study (i.e., worst-
case¼5.4), which was expected given mean score adjustments
were relatively unaffected by any of the covariates included in the
statistical model.
Safety
Local tolerability was judged as good or very good by 91e93% of
patients at the visit following administration, and patient- and
investigator-assessed global tolerability at the 4, 12 and 26-week
follow-up visits were nearly identical and comparable to local
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93% to 97% of the respondents. Therewere no statistically signiﬁcant
intergroup differences for any of these variables. Pain associated
with the initial injection of Sinovial or Synvisc in ITT patients
averaged 3.0 and 2.9, respectively, on a 10-point scale, declining
slightly to 2.9 and 2.7, respectively, and 2.7 and 2.6, respectively,
after the second and third injections. Of the adverse events reported
in this study, six were considered treatment-related, with ﬁve
events in four patients in the Synvisc group [injection site hema-
toma, injection site pain, arthralgia and joint swelling (two episodes
in one patient)] and one case of injection site pain in a patient who
received Sinovial. There were seven severe adverse events repor-
ted: six events in six Synvisc-treated patients, and one in
a Sinovial recipient. Serious adverse events were also relatively
rare, with ﬁve events among four Synvisc-treated patients, and
with one event in a Sinovial-treated patient. None of the serious
adverse events were thought to be treatment-related.
Discussion
It is evident from the results of this study that both preparations
were equally effective in improving clinical performance as
assessed through multiple outcome measures. Indeed, the magni-
tude of the reduction in WOMAC Questionnaire Pain Subscores for
patients given three consecutive weekly injections of Sinovialwas
shown to be non-inferior to Synvisc at each of the three post-
treatment visits, with the lower bound of the 95% CI generally being
well above the relatively conservative 8 mm protocol-deﬁned
non-inferiority margin, derived from clinical considerations
related to theminimum clinically perceptible difference inWOMAC
pain scores. Consistent with the ﬁnding of non-inferiority of
Sinovial in comparison to Synvisc with regard to the primary
efﬁcacy variable, there were no statistically signiﬁcant intergroup
differences for any of the 13 secondary outcome variables/time
intervals analyzed, except at 12 weeks following the initial hya-
luronic acid injection in which a higher percentage of patients in
the Sinovial group were found to be very satisﬁed with their
treatment course, in association with more favorable scoring for
Lequesne pain, investigator-assessed global status, and rescue
medication consumption for target knee pain.
In any study with pain as the primary outcome measure,
a potential source of confounding is concomitant usage of pain-
relieving therapies. In addressing this issue, an analysis was per-
formed in which success was deﬁned as a >30% reduction in the
WOMAC pain subscore at each of the three follow-up periods. This
analysis revealed that a larger proportion of the patients assigned
to the Synvisc group were classiﬁed as having failed treatment
due to concomitant pain therapy consumption at each of the
follow-up intervals, but especially at 4 and 12 weeks where the
intergroup differences attained statistical or near-statistical
signiﬁcance. Overall total success rates after adjusting for pain
therapy usage were correspondingly higher for the Sinovial-
treated patients at the earlier time-points as well. These data
indicate that the non-inferiority of Sinovial in comparison to
Synvisc was not due to excessive usage of a pain-relieving alter-
nate therapy by Sinovial patients, and suggest a genuine treat-
ment effect.
The safety data generated in this study are largely unremark-
able, with individual injections being generally well-tolerated, and
patient/investigator scoring for global tolerability indicating
widespread procedural acceptability. There were no statistically
signiﬁcant intergroup differences in the overall incidence of
adverse events or in severe, serious or suspected treatment-related
AEs. An increased risk of local adverse events associated with hylan
over hyaluronic acid has previously been reported23.The lack of a placebo arm could be considered a limitation of this
trial, but it must be considered that use of an intra-articular placebo
in trials such as this presents several problems. First, there are
ethical concerns associated with using an invasive procedure, such
as an injection, to deliver a placebo in a setting where hyaluronic
acid products are routinely used in clinical practice. Second, there
are methodological challenges involved in achieving a true placebo
when it is necessary to perform arthrocentesis and substitute
synovial ﬂuid with saline. For these ethical and methodological
reasons, it was considered appropriate to examine the test product
in terms of non-inferiority to a marketed product, the effectiveness
of which has already been demonstrated by means of randomized
placebo-controlled trials. Synvisc was chosen as a reference
product because in recent meta-analyses it displayed the greatest
effect size5,6.
While the use of intra-articular hyaluronan in knee osteoar-
thritis is a well-established treatment, the generalizability of the
ﬁndings in this study may be applied to those patients who fail to
respond to non-pharmacologic therapy and simple analgesics, or in
whom non-selective NSAIDs and cyclooxygenase-2 speciﬁc inhib-
itors are contraindicated or have been associated with lack of efﬁ-
cacy or adverse events.
In conclusion, Sinovial and Synvisc treatments were found to
be equivalent both in terms of efﬁcacy and safety.
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